Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 8
- Registration Number
- NCT00351039
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 62
- Registration Number
- NCT00350792
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Thoraxklinik-Heidelberg gGmbH
- Target Recruit Count
- 132
- Registration Number
- NCT00349089
- Locations
- 🇩🇪
Klinikum Bremen-Ost, Bremen, Germany
🇩🇪Westdeutsches Tumorzentrum, Essen, Germany
🇧🇪Ziekenhuis Oost Limburg, Genk, Belgium
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 153
- Registration Number
- NCT00334594
- Locations
- 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭Inselspital Bern, Bern, Switzerland
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland
A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT00330915
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Göteborg, Sweden
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 135
- Registration Number
- NCT00325234
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 89
- Registration Number
- NCT00320515
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00321308
- Locations
- 🇮🇹
Pfizer Investigational Site, Torino, Italy
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
- Conditions
- Interventions
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2010-07-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT00316225
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
- Conditions
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00315861
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.